APLP1 and APLP2 (βAPP like protein 1, 2) are known to have similar primary structures to APP (Amyloid precursor protein). In recent years, it has been reported that three length types of APLP1-derived Aβ (Amyloidβ)-like peptides, APL1β25, APL1β27 and APL1β28 that are generated by BACE (β-secretase) and γ-secretase are present in CSF (cerebrospinal fluid). The report also indicates that these APL1β peptides are secreted via similar processes to Aβ but they were not deposited in AD (Alzheimer disease) brain. Additionally, in some experiments using cultured cells, relative production of APL1β28 was regulated as well as that of Aβ42, and the usability of measuring of APL1β28 in CSF is suggested as a candidate surrogate marker for the Aβ42 in brain. Thus, APL1β peptides are expected to be novel biomarkers of AD research. This product can measure human APL1β25.
- Assay Description:
- Overnight incubation (4°C) + 30 min. (4°C) + 30 min. (RT) = Overnight + 1 hour total incubation time
- Catalog number:
- 27737
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- None provided
- design:
- Solid phase sandwich ELISA using 2 kinds of highly specific antibodies
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Protocol:
- Sample types:
- Cerebrospinal fluid and cell culture supernatant
- Sample volume:
- 100 μL of properly diluted unknown / determination
- standards:
- 8 standards, serially diluted from 1 prepared lyophilized standard
- Standard range:
- 0 / 9.38 - 600 pg/mL
- storage:
- 2 - 8°C
- sensitivity:
- 2.49 pg/mL
- Species:
- Human
- References: